Skip to content
Screener

Supernus Pharmaceuticals SUPN Trokendi XR — Total revenues

Other product segments

Qelbree
$77.84M+20.2%
GOCOVRI
$35.24M+14.8%
Royalty, licensing, and other revenues
$29.31M+274%
Collaboration revenue (ZURZUVAE)
$27.64M—
ONAPGO
$8.38M—
APOKYN
$7.73M-48.4%
Oxtellar XR
$7.42M-27.2%
Other
$4.67M-45.6%

Similar metrics at other companies

PROG Holdings logo
PRGOther revenue — Total revenues
$39.4M+134%
Sonida Senior Living logo
SNDAResident revenue — Total revenues
$108.43M+36.8%
Asset Entities logo
ASSTOther revenue — Total revenues
$43K+514%
LanzaTech Global, Inc. logo
LNZABiorefining revenue — Total revenues
$6.98M+145%
ALN
ALNYRoyalty revenue — Total revenues
$71.67M+79.3%
Hyatt Hotels logo
HContra revenue — Total revenues
-$17M-13.3%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.72B+14.3%
Enterprise value$2.57B+13.6%
P/S3.5×-0.1×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001356576-26-000022
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Net product sales
Qelbree$77,843$64,745
GOCOVRI35,24030,689
Trokendi XR9,47912,801
ONAPGO8,375—
APOKYN7,72814,976
Oxtellar XR7,42210,198
Other(1)4,6668,579

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Supernus Pharmaceuticals's trokendi XR — total revenues?
Supernus Pharmaceuticals (SUPN) reported trokendi XR — total revenues of $9.48M in Q1 2026.
How has Supernus Pharmaceuticals's trokendi XR — total revenues changed year-over-year?
Supernus Pharmaceuticals's trokendi XR — total revenues decreased by 26.0% year-over-year, from $12.8M to $9.48M.
What is the long-term trend for Supernus Pharmaceuticals's trokendi XR — total revenues?
Over 4 years (2021 to 2025), Supernus Pharmaceuticals's trokendi XR — total revenues has grown at a -38.9% compound annual growth rate (CAGR), from $304.82M to $42.42M.
What does trokendi XR — total revenues mean?
This metric represents the total gross or net revenue generated specifically from the sales of a single pharmaceutical product line. It serves as a primary indicator of the product's market adoption and commercial performance within the company's broader neuroscience portfolio.

Ask your AI about Supernus Pharmaceuticals's trokendi xr — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude